Eric Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, director of vascular intervention, Beth Israel Deaconess, section head, interventional cardiology and vascular research, Susan F. Smith Center for Outcomes Research, and associate professor of medicine, Harvard Medical School, explained some of the new bioresorbable stent scaffold technology that is being developed for use in PAD below the knee at CRT 2025.

Advances in bioresorbable stents show promise for treating PAD

Bioresorbable stents are back in the spotlight thanks to some significant progress from multiple medtech companies. Eric Secemsky, MD, discussed some of the biggest breakthroughs in this space at CRT 2025.

Thumbnail

Cannabis use increases risk of heart attack, stroke in young adults

“Asking about cannabis use should be part of clinicians' workup to understand patients' overall cardiovascular risk, similar to asking about smoking cigarettes,” one researcher said. Additional details will be presented at ACC.25 in Chicago.

The rapid rise of artificial intelligence (AI) has helped cardiologists, radiologists, nurses and other healthcare providers embrace precision medicine in a way that ensures more heart patients are receiving personalized care.

The revolution is here: AI’s growing role in cardiovascular imaging, interventional cardiology

AI has already made a massive impact on healthcare, especially in the fields of cardiology and radiology. With the FDA clearing more and more algorithms, this trend is only expected to grow as time goes on.

Howard Herrmann, MD, University of Pennsylvania, explains details of the SMART Trial 2-year results at CRT 2025, where Evolut performed better hemodynamically than the Sapien 3 TAVR valve in small annuli patients. The study included 87% women.

SMART 2-year TAVR hemodynamic data: Medtronic Evolut is better compared to Edwards Sapien in small annulus patients

Sponsored by Medtronic

Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

American College of Cardiology shares new guidance focused on evaluation, management of cardiogenic shock

The new document represents the ACC’s first Concise Clinical Guidance; it was designed to be an easy-to-use reference for keeping track of a complicated topic. 

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

TAVR or TAVI? Cardiologists want a single acronym for the popular heart procedure

Clinicians are asking the world's medical societies to come together and agree on one acronym for TAVR/TAVI to avoid unnecessary confusion going forward.

Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.

Thumbnail

TAVR linked to stronger valve performance than SAVR in new 5-year study

TAVR is associated with a significantly lower risk of bioprosthetic valve dysfunction than SAVR, according to new data presented at CRT 2025 and simultaneously published in JACC

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.